Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group.
about
Recombinant human interleukin 10 for induction of remission in Crohn's diseaseInterventions for prevention of post-operative recurrence of Crohn's diseaseRecombinant human interleukin 10 for induction of remission in Crohn's diseaseTransfection of IL-10 expression vectors into endothelial cultures attenuates alpha4beta7-dependent lymphocyte adhesion mediated by MAdCAM-1Reversal of experimental colitis disease activity in mice following administration of an adenoviral IL-10 vector.New treatment options for alcoholic hepatitisCurrent stage in inflammatory bowel disease: What is next?Fibrosis Related Inflammatory Mediators: Role of the IL-10 Cytokine FamilyThe relationship between the immune system and oral manifestations of inflammatory bowel disease: a reviewTreatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gammaImmune therapy in inflammatory bowel disease and models of colitis.Interleukin-10 suppression of myeloid cell activation--a continuing puzzle.Interleukin-10 improves left ventricular function in rats with heart failure subsequent to myocardial infarction.The pros and cons of immunomodulatory IL-10 gene therapy with recombinant AAV in a Cftr-/- -dependent allergy mouse model.Use of Wild Type or Recombinant Lactic Acid Bacteria as an Alternative Treatment for Gastrointestinal Inflammatory Diseases: A Focus on Inflammatory Bowel Diseases and Mucositis.IFN-γ-mediated induction of an apical IL-10 receptor on polarized intestinal epithelia.Pharmacological intervention studies using mouse models of the inflammatory bowel diseases: translating preclinical data into new drug therapies.Effects of adacolumn selective leukocytapheresis on plasma cytokines during active disease in patients with active ulcerative colitis.Review article: the immunoregulatory cytokine interleukin-10--a therapy for Crohn's disease?Antiadhesion molecule therapy in inflammatory bowel disease.Understanding host-adherent-invasive Escherichia coli interaction in Crohn's disease: opening up new therapeutic strategies.Review article: biological agents in the treatment of Crohn's disease.How informative is the mouse for human gut microbiota research?Novel therapies for the treatment of inflammatory airway disease.Oral interleukin-10 alleviates polyposis via neutralization of pathogenic T-regulatory cellsGene transfer approaches for the treatment of inflammatory bowel disease.Mucosal gene therapy using a pseudotyped lentivirus vector encoding murine interleukin-10 (mIL-10) suppresses the development and relapse of experimental murine colitis.Potential new drugs for therapy of chronic obstructive pulmonary disease.A systematic review of measurement of endoscopic disease activity and mucosal healing in Crohn's disease: recommendations for clinical trial design.Chronic obstructive pulmonary disease * 12: New treatments for COPDIntracellular accumulation of trehalose protects Lactococcus lactis from freeze-drying damage and bile toxicity and increases gastric acid resistance.An essential protective role of IL-10 in the immunological mechanism underlying resistance vs. susceptibility to lupus induction by dendritic cells and dying cells.Development of a pH-responsive particulate drug delivery vehicle for localized biologic therapy in inflammatory bowel diseaseInterleukin 37 expression protects mice from colitis.Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel diseaseAn interleukin 12 p40-IgG2b fusion protein abrogates T cell mediated inflammation: anti-inflammatory activity in Crohn's disease and experimental colitis in vivo.Interleukin-10 in the pathophysiology of inflammatory bowel disease: increased serum concentrations during the recovery phaseIL-10 and its related cytokines for treatment of inflammatory bowel disease.Interleukin-10 paradox: A potent immunoregulatory cytokine that has been difficult to harness for immunotherapy.Helicobacter bilis infection accelerates and H. hepaticus infection delays the development of colitis in multiple drug resistance-deficient (mdr1a-/-) mice
P2860
Q24236636-5108A053-4E18-46D7-B87B-7C6E0AEDC09AQ24240542-FA1DBB0A-CDAA-42E8-A423-EC969CA2717DQ24243040-791B5A94-B776-4A96-A942-9B96DFE8EB3EQ24805188-A8CD028C-E725-40E4-BCED-609C0BF1C1A2Q24812028-C760D8E6-EF1E-4358-9BEC-ED1185834303Q26751402-AD19CCCD-8416-40F6-A162-50CC56ADD195Q26777429-AB3196C9-99FF-4CE5-A2C1-FDE669F6DB4AQ26801150-55197480-1842-4E14-BC24-A74407A16537Q28078219-F9A251B3-C922-4819-B218-7C77EA6F37E3Q28344937-E43F4C7C-B6BC-46E4-A961-B0F0026E16A3Q30774968-8C527E10-0C5B-4B3E-8060-C5BE9DF30E0DQ33340529-2A942494-FE9A-440E-97B7-726A0D0DE405Q33348902-4FC11801-A446-433C-AC69-C0F9970F23D6Q33381294-FF7E6F78-968D-410A-B90C-0174D9424330Q33650357-83A94F4E-0422-492C-A1BB-9FF97B7778F2Q33702103-6F83EC8E-3296-49DD-84D9-ED59C3BADC01Q33818370-7F563D7B-9804-4754-81C9-5BBDEB41436BQ33867970-3EA36CE8-14BC-405C-A42B-67D82C539A99Q34421477-C270CFE4-2A92-49CD-86E4-235C19E762B5Q34752319-C7DBF3EA-77C3-4E64-9C0C-99DE4D430CD9Q34786166-C1514604-8BE6-4DB1-8E26-956FDD533285Q34799343-691B31AA-CF9B-41DC-9790-AD5877799131Q34818253-61CEC419-4217-4C80-9332-087E9B8BF282Q35040779-98A87803-0C47-43DE-AAFF-B7ECF3B9E605Q35067193-4D5CED99-5652-4301-8A47-0E96DEA5CC0FQ35122162-E4A90281-612F-459A-9753-C514D61A3916Q35142393-FA6EAABE-4480-44B9-BECC-84581EBC94F9Q35164728-4EC2F593-10FB-40CF-A257-E5F6F456DFEBQ35207745-17846B4B-4E54-421E-822B-D7069F017271Q35208742-14F717E7-A7A9-4197-90F0-5BCB8B982268Q35215742-6CEC5717-2BC8-45CB-B06A-A7989DEEF1D0Q35223219-F43AF098-E94D-4203-A96A-897F6DD851ABQ35228674-4162A6FB-1B1C-44C4-BCD4-BFAE8D285EA0Q35289509-1B258B0E-E7B5-4D3C-9864-3E5DEB7B003AQ35594920-4A83D4D8-51DE-4104-B0DE-56523B808D4DQ35596317-3721E949-55E2-47E2-B09C-158EFE3C8C9EQ35598569-B86F5294-B02D-4BBE-8A4B-B0C0D53397C0Q35678651-32368F46-E5AE-49EB-8E8B-D755C4190545Q35680472-CB80812C-B534-4D2A-AA22-2BAE530FDBDBQ35747283-A9F2C997-14CD-4295-95DE-8AA27F77CA4F
P2860
Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group.
description
2000 nî lūn-bûn
@nan
2000 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Recombinant human interleukin ...... sease Cooperative Study Group.
@ast
Recombinant human interleukin ...... sease Cooperative Study Group.
@en
Recombinant human interleukin ...... sease Cooperative Study Group.
@nl
type
label
Recombinant human interleukin ...... sease Cooperative Study Group.
@ast
Recombinant human interleukin ...... sease Cooperative Study Group.
@en
Recombinant human interleukin ...... sease Cooperative Study Group.
@nl
prefLabel
Recombinant human interleukin ...... sease Cooperative Study Group.
@ast
Recombinant human interleukin ...... sease Cooperative Study Group.
@en
Recombinant human interleukin ...... sease Cooperative Study Group.
@nl
P2093
P921
P356
P1433
P1476
Recombinant human interleukin ...... sease Cooperative Study Group.
@en
P2093
Fedorak RN
Hanauer SB
Rutgeerts P
Schreiber S
P304
P356
10.1053/GAST.2000.20229
P407
P577
2000-12-01T00:00:00Z